608 related articles for article (PubMed ID: 15911236)
1. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20.
Postma TJ; Aaronson NK; Heimans JJ; Muller MJ; Hildebrand JG; Delattre JY; Hoang-Xuan K; Lantéri-Minet M; Grant R; Huddart R; Moynihan C; Maher J; Lucey R;
Eur J Cancer; 2005 May; 41(8):1135-9. PubMed ID: 15911236
[TBL] [Abstract][Full Text] [Related]
2. Background noise: the experience of chemotherapy-induced peripheral neuropathy.
Bakitas MA
Nurs Res; 2007; 56(5):323-31. PubMed ID: 17846553
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
Cheng HL; Molassiotis A
Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
[TBL] [Abstract][Full Text] [Related]
4. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population.
Mols F; van de Poll-Franse LV; Vreugdenhil G; Beijers AJ; Kieffer JM; Aaronson NK; Husson O
Eur J Cancer; 2016 Dec; 69():28-38. PubMed ID: 27814471
[TBL] [Abstract][Full Text] [Related]
5. Development of a disease-specific Quality of Life questionnaire module for patients with gastrointestinal neuroendocrine tumours.
Davies AH; Larsson G; Ardill J; Friend E; Jones L; Falconi M; Bettini R; Koller M; Sezer O; Fleissner C; Taal B; Blazeby JM; Ramage JK;
Eur J Cancer; 2006 Mar; 42(4):477-84. PubMed ID: 16412628
[TBL] [Abstract][Full Text] [Related]
6. A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer.
Kuroi K; Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Ohsumi S; Watanabe T; Bain S; Hausheer FH
Jpn J Clin Oncol; 2008 Nov; 38(11):748-54. PubMed ID: 18845520
[TBL] [Abstract][Full Text] [Related]
7. The EORTC QLQ-HDC29: a supplementary module assessing the quality of life during and after high-dose chemotherapy and stem cell transplantation.
Velikova G; Weis J; Hjermstad MJ; Kopp M; Morris P; Watson M; Sezer O;
Eur J Cancer; 2007 Jan; 43(1):87-94. PubMed ID: 17081744
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.
Beijers AJ; Vreugdenhil G; Oerlemans S; Eurelings M; Minnema MC; Eeltink CM; van de Poll-Franse LV; Mols F
Support Care Cancer; 2016 Jun; 24(6):2411-20. PubMed ID: 26634561
[TBL] [Abstract][Full Text] [Related]
9. Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data.
Smith EML; Zanville N; Kanzawa-Lee G; Donohoe C; Bridges C; Loprinzi C; Le-Rademacher J; Yang JJ
Support Care Cancer; 2019 Jul; 27(7):2599-2608. PubMed ID: 30460399
[TBL] [Abstract][Full Text] [Related]
10. Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18.
Blazeby JM; Currie E; Zee BC; Chie WC; Poon RT; Garden OJ;
Eur J Cancer; 2004 Nov; 40(16):2439-44. PubMed ID: 15519517
[TBL] [Abstract][Full Text] [Related]
11. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin.
Alberti P; Rossi E; Cornblath DR; Merkies IS; Postma TJ; Frigeni B; Bruna J; Velasco R; Argyriou AA; Kalofonos HP; Psimaras D; Ricard D; Pace A; Galiè E; Briani C; Dalla Torre C; Faber CG; Lalisang RI; Boogerd W; Brandsma D; Koeppen S; Hense J; Storey D; Kerrigan S; Schenone A; Fabbri S; Valsecchi MG; Cavaletti G;
Ann Oncol; 2014 Jan; 25(1):257-64. PubMed ID: 24256846
[TBL] [Abstract][Full Text] [Related]
12. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
Park KU
Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
[TBL] [Abstract][Full Text] [Related]
13. Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool.
Tofthagen CS; McMillan SC; Kip KE
Cancer Nurs; 2011; 34(4):E10-20. PubMed ID: 21242773
[TBL] [Abstract][Full Text] [Related]
14. The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module: EORTC QLQ-CX24.
Greimel ER; Kuljanic Vlasic K; Waldenstrom AC; Duric VM; Jensen PT; Singer S; Chie W; Nordin A; Bjelic Radisic V; Wydra D;
Cancer; 2006 Oct; 107(8):1812-22. PubMed ID: 16977652
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced peripheral neuropathy: assessment of oncology nurses' knowledge and practice.
Binner M; Ross D; Browner I
Oncol Nurs Forum; 2011 Jul; 38(4):448-54. PubMed ID: 21708535
[TBL] [Abstract][Full Text] [Related]
16. Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy.
Yeo F; Ng CC; Loh KWJ; Molassiotis A; Cheng HL; Au JSK; Leung KT; Li YC; Wong KH; Suen L; Chan CW; Yorke J; Farrell C; Bandla A; Ang E; Lopez V; Sundar R; Chan A
Support Care Cancer; 2019 Dec; 27(12):4753-4762. PubMed ID: 30972646
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools.
Cavaletti G; Frigeni B; Lanzani F; Mattavelli L; Susani E; Alberti P; Cortinovis D; Bidoli P
Eur J Cancer; 2010 Feb; 46(3):479-94. PubMed ID: 20045310
[TBL] [Abstract][Full Text] [Related]
18. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale.
Cavaletti G; Frigeni B; Lanzani F; Piatti M; Rota S; Briani C; Zara G; Plasmati R; Pastorelli F; Caraceni A; Pace A; Manicone M; Lissoni A; Colombo N; Bianchi G; Zanna C;
J Peripher Nerv Syst; 2007 Sep; 12(3):210-5. PubMed ID: 17868248
[TBL] [Abstract][Full Text] [Related]
19. Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).
Binda D; Vanhoutte EK; Cavaletti G; Cornblath DR; Postma TJ; Frigeni B; Alberti P; Bruna J; Velasco R; Argyriou AA; Kalofonos HP; Psimaras D; Ricard D; Pace A; Galiè E; Briani C; Dalla Torre C; Lalisang RI; Boogerd W; Brandsma D; Koeppen S; Hense J; Storey D; Kerrigan S; Schenone A; Fabbri S; Rossi E; Valsecchi MG; Faber CG; Merkies IS; ; Galimberti S; Lanzani F; Mattavelli L; Piatti ML; Bidoli P; Cazzaniga M; Cortinovis D; Lucchetta M; Campagnolo M; Bakkers M; Brouwer B; Boogerd W; Grant R; Reni L; Piras B; Pessino A; Padua L; Granata G; Leandri M; Ghignotti I; Plasmati R; Pastorelli F; Heimans JJ; Eurelings M; Meijer RJ; Grisold W; Lindeck Pozza E; Mazzeo A; Toscano A; Russo M; Tomasello C; Altavilla G; Penas Prado M; Dominguez Gonzalez C; Dorsey SG
Eur J Cancer; 2013 Sep; 49(13):2910-8. PubMed ID: 23668917
[TBL] [Abstract][Full Text] [Related]
20. Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes.
Li T; Timmins HC; Trinh T; Mizrahi D; Harrison M; Horvath LG; Grimison P; Friedlander M; Kiernan MC; King MT; Rutherford C; Goldstein D; Park SB
J Natl Compr Canc Netw; 2023 Feb; 21(2):125-132.e3. PubMed ID: 36791763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
